Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MOBI
Strong SellSinkerMobia Medical, Inc. · Healthcare · United States · $378M · Avg Vol: $2M/d
15
StockRankGet insider-trade alerts
Q
41
V
30
M
24
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Revenue | 15.6M | 32.0M | 45.3M | 55.1M | 78.8M | 56.8% |
| EPS | -1.08 | -0.02 | -1.93 | -3.07 | -2.20 | — |
| Shares | 33.1M | 33.1M | 33.3M | — | — | — |
| Debt | 7.7M | 8.4M | 8.4M | — | — | — |
| Equity | -106.0M | -150.8M | — | — | — | — |
| Op CF | -24.3M | -45.7M | -58.4M | — | — | — |
| Inv CF | -40.8K | -0.4M | — | — | — | — |
| Fin CF | 15.7M | 65.0M | — | — | — | — |
Loading 1Y...
PRICE (1Y)+3.7%
SMA 50SMA 200
Close
$10.82
RSI (14)
45.5
SCORE BREAKDOWN
Quality
41
ROIC
-120.0%5.2
ROE
—N/A
GP/Assets
76.9%95.5
Op. Margin
-132.7%15.6
FCF/Assets
-95.7%2.3
Piotroski
549.3
Int. Cover
-47.1x12.0
D/E Ratio
0.05x71.5
Current Ratio
13.28x91.4
Value
30
P/E (TTM)
—N/A
EV/EBITDA
-3.6x25.0
P/FCF
—N/A
P/B
2.2x57.9
P/S
8.5x28.8
Div Yield
—N/A
Momentum
24
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
-1.5%23.4
EPS Rev 12W
—N/A
EPS Improve
-14%16.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$378M
P/E (Forward)
-5.3x
Gross Margin
81.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MOBI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MOBI | Mobia Medical, Inc.(you) | $378M | 15 | Strong Sell |
| PACB | Pacific Biosciences of California, Inc. | $435M | 16 | Strong Sell |
| CATX | Perspective Therapeutics, Inc. | $355M | 12 | Strong Sell |
| CV | CapsoVision, Inc. | $297M | 13 | Strong Sell |
| RXST | RxSight, Inc. | $293M | 19 | Strong Sell |
| CLPT | ClearPoint Neuro, Inc. | $474M | 10 | Strong Sell |
| TLSI | TriSalus Life Sciences, Inc. | $297M | 20 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
| OFIX | Orthofix Medical Inc. | $392M | 27 | Sell |
| IMR.AX | Imricor Medical Systems, Inc. | $506M | 6 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.1%